Phase III CANOPY-2 trial did not meet primary endpoint of overall survival in patients with advanced or metastatic non-small cell lung cancer whose cancer progressed while on or after previous treatments1Canakinumab development program continues; two P…
The COVID-19 pandemic created a number of different challenges for the patient community. Through those challenges, however, came opportunities to utilise digital engagement, and an accelerated use of digital tools. Participants of the European Patient…
The COVID-19 pandemic created a number of different challenges for the patient community. Through those challenges, however, came opportunities to utilise digital engagement, and an accelerated use of digital tools. Participants of the European Patient…
At Novartis, we believe in gender equity. We continue to choose to challenge inequity, including through our public pledge with the Equal Pay International Coalition (EPIC) to achieve gender balance in management and further improve our pay equity and …
At Novartis, we believe in gender equity. We continue to choose to challenge inequity, including through our public pledge with the Equal Pay International Coalition (EPIC) to achieve gender balance in management and further improve our pay equity and …
At Novartis, we believe in gender equity. We continue to choose to challenge inequity, including through our public pledge with the Equal Pay International Coalition (EPIC) to achieve gender balance in management and further improve our pay equity and …
Shannon Klinger, Chief Legal Officer, to leave Novartis on March 15, 2021Thomas Kendris appointed Chief Legal Officer ad interimBasel, March 5, 2021 — Novartis announced today that Shannon Thyme Klinger, Chief Legal Officer, has decided to resign from …
Novartis to support global supply of another COVID-19 vaccine, leveraging manufacturing capacity and capabilities to help address pandemic.Novartis plans to manufacture the mRNA and bulk drug product of the CVnCoV vaccine candidate for up to 50 million…
Shareholders approve 24th consecutive dividend increase to CHF 3.00 (+1.7%) per share for 2020; representing a 3.8% yield1 and approximately 63% payout of free cash flowShareholders confirm Dr. Joerg Reinhardt as Chairman of the Board of Directors as w…
“Planetary health is directly related to human health and if we don’t change, the human species will disappear.” This was the stark warning delivered by Patrice Matchaba, Head, US Corporate Responsibility and President, Novartis US Foundation, at the i…